ClinVar Miner

Submissions for variant NM_000531.6(OTC):c.418G>C (p.Ala140Pro) (rs72556260)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GenMed Metabolism Lab RCV000083431 SCV000115517 pathogenic not provided no assertion criteria provided not provided Converted during submission to Pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000587672 SCV000697261 likely pathogenic Ornithine carbamoyltransferase deficiency 2016-12-15 criteria provided, single submitter clinical testing Variant summary: The OTC c.418G>C (p.Ala140Pro) variant involves the alteration of a conserved nucleotide and results in a replacement of a small size and hydrophobic Alanine (A) with a medium size and hydrophobic Proline (P) in the Carbamoyl phosphate binding domain of the OTC enzyme (ACMG-PM1). 5/5 in silico tools predict a damaging outcome for this substitution (ACMG-PP3). This variant is absent form the general population (ExAC) (ACMG-PM2) while it was reported in at-least 3 biochemically and clinically well characterized neonatal onset OTC deficiency patients indicating causality. In addition, at-least one clinical diagnostic laboratory has classified this variant as pathogenic (ACMG-PP5). However, the effect of this variant on functional OTC enzyme deficiency has not been reported. Taken together, this variant is classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.